Cure8 research brief
Micronutrient deficiencies are common in IBD and can worsen anemia, healing, and neurologic function. This study shows inpatient testing focuses on B12 while missing other commonly deficient nutrients (B1, B6, zinc), suggesting opportunities to align practice with guideline recommendations.
Clinicians treating hospitalized IBD patients, hospital nutrition services, IBD researchers, and patients concerned about nutritional deficiencies.
This study reviewed inpatient records at a tertiary center to compare how often IBD patients hospitalized for a flare had micronutrient testing (vitamins B1, B6, B12, and zinc) and how often tests identified deficiencies. B12 was almost universally tested (97%), while B6, B1, and zinc were tested far less often (35%, 31%, and 19%).
Among those tested, deficiencies were common and more frequent for B6, zinc, and B1 than for B12. The authors describe this as a testing–yield mismatch and an implementation gap between guideline recommendations for comprehensive assessment and real-world inpatient practice.
The findings do not prove that routine panel-based testing improves outcomes; the study is retrospective and selective testing could bias observed yields. The authors suggest prospective evaluation to see whether more systematic testing changes clinical care or patient-important outcomes.
Retrospective single-center design and selective testing of non-B12 nutrients can inflate per-test deficiency yield; the study does not provide evidence that broader testing changes patient outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests most adults with chronic diarrhea in this tertiary setting had organic/inflammatory disease and identifies accessible clinical and lab predictors that could help prioritize endoscopic evaluation.
Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
